Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | Current thought on treating chronic lymphocytic leukemia

Jeffrey Jones • 9 Jun 2016
EHA 2016
Chronic Lymphocytic Leukemia

Jeffrey Jones, MD, MPH from the Ohio State University, Columbus, OH discusses the current thought on treating relapsed and refractory chronic lymphocytic leukemia (CLL). This is an area where one can see a tremendous revolution in CLL treatment. Treatment has moved from once being mostly chemotherapy to more specifically targeting the abnormal biology of CLL. In order to do this there needs to be a fundamental understanding of CLL, specifically what drives CLL growth and survival. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark

More from Jeffrey Jones

3:46
The characteristics and mode of action of ibrutinib for CLL
Jeffrey Jones • 9 Jun 2016
4:02
Evaluation 17p del CLL patients treated with ibrutinib: cross-study analysis of treatment outcomes
Jeffrey Jones • 9 Jun 2016

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals